Lucid Diligence Brief: Cytotheryx $60 million Series A in liver cell therapy
Lucid Diligence Brief: Cytotheryx $60 million Series A in liver cell therapy…
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy…
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in IBD
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in……
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s deal
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s…
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized CRISPR
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized…
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences Professional…
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan Professional…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary…
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase…